Insights Into Breast Cancer

Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer. Insights on current treatment practice attitudes toward recently introduced and upcoming agents

Meeting Moderator

Sushil Bhardwaj, MD

Good Samaritan Hospital Suffern, NY, USA

Look Inside This Report

Download a sample of this report and start discovering the insights

Report Snapshot

Insights on the following breast cancer therapies were obtained

  • HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, HDAC inhibitors, chemotherapies
  • HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, neratinib, AIs, mTOR inhibitors, chemotherapies
  • TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan, GPNMB), immunotherapy, chemotherapies


  • A roundtable discussion, moderated by an Axess Oncology Network Physician, focusing on treatment of metastatic breast cancer was held on August 24, 2019, in Washington, DC, US
  • Disease state and data presentations were developed in conjunction with a medical expert from the University of Pittsburgh
  • The group of advisors comprised 14 community oncologists from the Northeast, US
  • Data collection was accomplished through use of audience response system questioning and moderated discussion

Explore Available and Upcoming Insight Reports

View Reports